Abstract
Although prodromal symptoms of psychosis have long been recognized, the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. Over the last fifteen years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms. This clinical syndrome has been termed an “At Risk Mental State”, and operationalised criteria, the “Ultra High Risk (UHR)”, or “Clinical High Risk” criteria, have been developed to identify the syndrome. We will review here the mainstreams of the UHR paradigms focusing on the conceptual basis, potentials and limtations in current psychiatric research.
Keywords: Psychosis, schizophrenia, prodrome, At Risk Mental State, Ultra High Risk (UHR), Clinical High Risk, subthreshold, depression, mania, Risk Syndrome
Current Pharmaceutical Design
Title: The Ultra High Risk Approach to Define Psychosis Risk
Volume: 18 Issue: 4
Author(s): Alison R. Yung, Paolo Fusar-Poli and Barnaby Nelson
Affiliation:
Keywords: Psychosis, schizophrenia, prodrome, At Risk Mental State, Ultra High Risk (UHR), Clinical High Risk, subthreshold, depression, mania, Risk Syndrome
Abstract: Although prodromal symptoms of psychosis have long been recognized, the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. Over the last fifteen years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms. This clinical syndrome has been termed an “At Risk Mental State”, and operationalised criteria, the “Ultra High Risk (UHR)”, or “Clinical High Risk” criteria, have been developed to identify the syndrome. We will review here the mainstreams of the UHR paradigms focusing on the conceptual basis, potentials and limtations in current psychiatric research.
Export Options
About this article
Cite this article as:
R. Yung Alison, Fusar-Poli Paolo and Nelson Barnaby, The Ultra High Risk Approach to Define Psychosis Risk, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316299
DOI https://dx.doi.org/10.2174/138161212799316299 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Current Alzheimer Research Chemistry, Biological Properties and SAR Analysis of Quinoxalinones
Mini-Reviews in Medicinal Chemistry CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective
Current Stem Cell Research & Therapy Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Prion-like Mechanisms in Alzheimer's Disease
Current Alzheimer Research 6-Benzothiazolyl Ureas, Thioureas and Guanidines are Potent Inhibitors of ABAD/17β-HSD10 and Potential Drugs for Alzheimer"s Disease Treatment: Design, Synthesis and in vitro Evaluation
Medicinal Chemistry Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Nuclear Receptors as Potential Molecular Targets in Cholesterol Accumulation Conditions: Insights from Evidence on Hepatic Cholesterol Degradation and Gallstone Disease in Humans
Current Medicinal Chemistry Lack of Association Between SLC24A4 Polymorphism and Late-onset Alzheimer's Disease in Han Chinese
Current Neurovascular Research Cross-Talk Between NO Synthase Isoforms in Neuro-Inflammation: Possible Implications in HIV-Associated Neurocognitive Disorders
Current Medicinal Chemistry Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews Off-Label Trazodone Prescription: Evidence, Benefits and Risks
Current Pharmaceutical Design Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Automatic Detection of Cognitive Impairments through Acoustic Analysis of Speech
Current Alzheimer Research Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer’s Disease in Subjects with Mild Cognitive Impairment
Current Alzheimer Research Adaptive Behavior in Williams-Beuren Syndrome, Down Syndrome, and Autism Spectrum Disorder
Current Psychiatry Reviews Infective Proteins: The Prion Puzzle
Current Protein & Peptide Science Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science